SCYNEXIS, Inc. Capital Expenditures Incurred but Not yet Paid
SCYNEXIS, Inc. (SCYX) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-03-31
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-12-31 was $0.00.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $78.00K.
- SCYNEXIS, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 derived: sum of 3 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | -$478.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | -$478.00K derived: sum of 3 quarters · filed 2023-03-31 | -$243.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 | -$478.00K derived: sum of 2 quarters · filed 2023-03-31 | -$243.00K derived: sum of 3 quarters · filed 2023-03-31 | -$100.00K derived: sum of 4 quarters · filed 2023-03-31 |
| 2021-12-31 | -$478.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$243.00K derived: sum of 2 quarters · filed 2023-03-31 | -$100.00K derived: sum of 3 quarters · filed 2023-03-31 | $78.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $378.00K derived: sum of 2 quarters · filed 2022-11-09 | $556.00K 10-Q · filed 2022-11-09 | $556.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $321.00K 10-Q · filed 2022-08-15 | $321.00K derived: sum of 3 quarters · filed 2022-08-15 | $321.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $178.00K 10-Q · filed 2022-05-12 | $178.00K derived: sum of 2 quarters · filed 2022-05-12 | $178.00K derived: sum of 3 quarters · filed 2022-05-12 | $178.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $0.00 derived: sum of 3 quarters · filed 2022-03-29 | $0.00 10-K · filed 2022-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $0.00 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |